Annexon, Inc. (NASDAQ:ANNX – Get Rating) – Cantor Fitzgerald upped their FY2023 earnings per share (EPS) estimates for shares of Annexon in a research note issued on Tuesday, March 14th. Cantor Fitzgerald analyst P. Stavropoulos now expects that the company will post earnings per share of ($2.15) for the year, up from their previous forecast of ($2.60). Cantor Fitzgerald currently has a “Overweight” rating and a $18.00 target price on the stock. The consensus estimate for Annexon’s current full-year earnings is ($2.16) per share.
Annexon (NASDAQ:ANNX – Get Rating) last announced its quarterly earnings data on Monday, March 6th. The company reported ($0.48) earnings per share for the quarter, beating the consensus estimate of ($0.53) by $0.05.
Several other equities research analysts also recently issued reports on ANNX. HC Wainwright reiterated a “buy” rating and issued a $30.00 target price on shares of Annexon in a research note on Tuesday, March 7th. Needham & Company LLC reiterated a “buy” rating and issued a $24.00 target price on shares of Annexon in a research note on Tuesday, March 7th. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Annexon currently has an average rating of “Buy” and an average target price of $19.80.
Annexon Price Performance
Shares of NASDAQ ANNX opened at $4.07 on Friday. The stock has a market capitalization of $205.49 million, a price-to-earnings ratio of -1.42 and a beta of 0.53. The business has a 50-day moving average of $5.92 and a 200-day moving average of $5.72. Annexon has a fifty-two week low of $2.06 and a fifty-two week high of $7.65.
Institutional Investors Weigh In On Annexon
Hedge funds have recently bought and sold shares of the stock. Laurion Capital Management LP acquired a new stake in Annexon during the second quarter worth approximately $48,000. EWG Elevate Inc. acquired a new stake in Annexon during the third quarter worth approximately $62,000. Fairmount Funds Management LLC lifted its position in Annexon by 16.1% during the third quarter. Fairmount Funds Management LLC now owns 3,358,563 shares of the company’s stock worth $20,756,000 after acquiring an additional 465,963 shares during the last quarter. Woodline Partners LP acquired a new stake in Annexon during the second quarter worth approximately $1,544,000. Finally, DAFNA Capital Management LLC increased its holdings in shares of Annexon by 32.5% during the second quarter. DAFNA Capital Management LLC now owns 40,796 shares of the company’s stock worth $154,000 after purchasing an additional 10,000 shares during the period.
Annexon Company Profile
Annexon, Inc, a clinical-stage biopharmaceutical company, discovers and develops therapeutics for autoimmune, neurodegenerative, and ophthalmic disorders. The company’s C1q is an initiating molecule of the classical complement pathway that targets distinct disease processes, such as antibody-mediated autoimmune disease and complement-mediated neurodegeneration.
Read More
Receive News & Ratings for Annexon Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Annexon and related companies with MarketBeat.com’s FREE daily email newsletter.